Mytho | Neocartil™ PRO

STATE OF THE ART

Mythocondro® is the first Non-Animal Chondroitin Sulfate (CS) obtained through a fermentation-based manufacturing process providing a reliable and reproducible source of product. Mythocondro® solves any concerns related to the production origin, the possible presence of transmissible infective agents, the contaminations and adulterations typical of animal-derived raw materials and promises to completely change the global CS industry.

Produced by fermentative process: non-animal production
High purity and quality profile guaranteed by controlled, reliable and reproducible controlled process
Very low protein content and a substantial absence of unusually sulfated and oversulfated disaccharides
Demonstrated biological activity and established safety with published results Easy handling and storage. Low molecular weight and enhanced bioavailability

ANIMAL CS CONCERNS

Animal chondroitin sulfate is totally derived from animal sources. Animal CS generally relies on bovine, porcine, chicken or cartilaginous fish such as sharks and raja by-products, in particular cartilage, as raw material. A mix of all these sources is possible producing a CS final product having mixed characteristics and low efficacy.

Chondroitin Sulfate is extracted from cartilaginous feedstocks using organic solvents, with long purification processes that may cause chemical degradation/desulfation and loss of activity along with an uncontrolled and unreliable supply chain of CS raw materials.

Animal Chondroitin Sulfate: highly heterogenous

MOST SIMILAR

Mythocondro® sulfation pattern is similar to human synovial fluid with homogeneous structure and physicochemical properties. The presence of sulfate groups in defined positions as in the human synovial fluid.

FERMENTATION-DERIVED PRODUCTION

Based on good five patents, the innovative production method of Mythocondro® is the natural biosynthesis from a specific, non-GMO bacterial strain that produces capsular polysaccharides, showing homology with the chain of biological chondroitin. The result of this innovative approach is the only Non- Animal CS, with homogeneous structure and the presence of sulfate groups in de ned positions as well as found in chondroitin of human.

VERY LOW PROTEIN CONTENT (≤ 0.5%)

Current pharmacopoeia limits alow a protein content up to 6.0% (USP) and 3.0% (EP)

LOW MOLECULAR WEIGHT

Mythocondro® has a constant charge density and molecular mass parameters: low molecular weight = 9kDa with homogeneous pro le and low polydispersitry

MYTHOCONDRO® STUDIES

Mythocondro® was tested for efficacy both in vitro and in vivo with evaluation of:

Intestinal epithelial permeability compared to animal Chondroitin Sulfates
Efficacy and activity in an induced Adjuvant Arthritis (AA) model in rats
Anti-inflammatory effect compared to animal Chondroitin Sulfate (production of pro-inflammatory cytokines and C-reactive protein in plasma)

Effects of Mythocondro® on arthritic score

Mythocondro® showed the in vivo ability to improve many parameters. Oral daily administration over four weeks ameliorated the arthritic score, involving inflammation at joint level and hind paw swelling, and prevented the inflammation-related body weight loss. The study included healthy animals, untreated arthritic animals and arthritic animals who received 900 mg/kg daily of bovine CS, and Mythocondro®.

Enhanced bioavailability: +43%

In this human clinical trial Mythocondro® showed a higher bioavailability of 43%, versus bovine CS, with an increased Area Under the Curve (AUC0-24h). This behavior highlights Mythocondro® capacity to be better absorbed if compared to bovine CS. In particular, 5h after administration, the plasmatic concentration of Mythocondro® remains 89% higher than bovine CS.

Mythocondro is registered trademark of GNOSIS S.P.A. Sede Legale: Piazza del Carmine, 4 20121 Milano. Above data showed by permission of Gnosis S.P.A.